Pterygium is a degenerative disease that characterized by excessive fibrovascular proliferation. To reduce the recurrence rate, surgery is the main strategy, in combination with adjacent procedures or adjunctive therapy. One of the most common adjunctive agents, mitomycin C (MMC), is known as an alkylating agent that inhibits fibroblast proliferation but is limitedly applied in pterygium due to various complications. A previous study demonstrated that activated pterygium subconjunctival fibroblasts overexpressed low-density lipoprotein (LDL) receptors. In this study, we designed and synthesized MMC-loaded mesoporous silica nanoparticles conjugated with LDL (MMC@MSNs-LDL) to deliver MMC into activated pterygium fibroblasts in a targeted manner. The MMC loading efficiency was approximately 6%. The cell viability test (CCK-8 assay) revealed no cytotoxicity for the empty carrier MSNs at a concentration of ≤1 mg/ml after administration for 48 h in subconjunctival fibroblasts. Primary pterygium and normal human subconjunctival fibroblasts with or without stimulation by vascular endothelial growth factor (VEGF) were treated as follows: 1) 10 μg/ml MMC@MSNs-LDL for 24 h (MMC concentration: 0.6 μg/ml); 2) 0.2 mg/ml MMC for 5 min then cultured for 24 h after MMC removal; and 3) normal culture without any drug treatment. At 24 h, the anti-proliferative effect of MMC@MSNs-LDL in activated pterygium fibroblasts was similar to that of MMC (cell viability: 46.2 ± 5.5% vs 40.5 ± 1.1%, respectively, P = 0.349). Furthermore, the cytotoxicity of MMC@MSNs-LDL to normal fibroblasts with or without VEGF stimulation was significantly lower than that of traditional MMC (cell viability: 75.6 ± 4.4% vs 36.0 ± 1.5%, respectively, P < 0.001; 84.7 ± 5.5% vs 35.7 ± 1.3%, P < 0.001). The binding of fluorescently labeled MMC@MSNs-LDL in fibroblasts was assessed using confocal fluorescence microscopy. The uptake of targeted nanoparticles in fibroblasts was time dependent and saturated at 6 h. VEGF-activated pterygium fibroblasts showed more uptake of MMC@MSNs-LDL than normal fibroblasts with or without VEGF activation (both P < 0.001). Our data strongly suggest that MMC@MSNs-LDL had an effective antiproliferative role in activated pterygium fibroblasts, with reduced toxicity to normal fibroblasts compared to traditional application of MMC. LDL-mediated drug delivery might have great potential in the management of pterygium recurrence.

译文

翼状胬肉是一种退行性疾病,其特征是纤维血管过度增生。为了降低复发率,手术是主要策略,结合邻近手术或辅助治疗。丝裂霉素c (MMC) 是最常见的辅助药物之一,被称为抑制成纤维细胞增殖的烷化剂,但由于各种并发症而被限制在翼状胬肉中。先前的研究表明,激活的翼状胬肉结膜下成纤维细胞过表达低密度脂蛋白 (LDL) 受体。在这项研究中,我们设计并合成了与LDL偶联的MMC负载的介孔二氧化硅纳米颗粒 (MMC @ msn-ldl),以靶向方式将MMC递送到活化的翼状胬肉成纤维细胞中。MMC加载效率约为6%。细胞活力测试 (CCK-8测定) 显示,在结膜下成纤维细胞中给药48小时后,浓度 ≤ 1 mg/ml的空载体MSNs没有细胞毒性。经血管内皮生长因子 (VEGF) 刺激或不刺激的原发性翼状胬肉和正常人结膜下成纤维细胞处理如下: 1) 10 μ g/ml MMC @ msn-ldl 24 h (MMC浓度: 0.6 μ g/ml); 2) 0.2 mg/ml MMC 5 min,然后在MMC去除后培养24 h; 3) 正常培养,无需任何药物处理。在24小时,MMC @ MSNs-LDL在活化的翼状胬肉成纤维细胞中的抗增殖作用与MMC相似 (细胞活力: 分别为46.2 ± 5.5% vs 40.5 ± 1.1%,P = 0.349)。此外,MMC @ MSNs-LDL对具有或不具有VEGF刺激的正常成纤维细胞的细胞毒性显着低于传统MMC (细胞活力: 分别为75.6 ± 4.4% vs 36.0 ± 1.5%,P <0.001; 84.7 ± 5.5% vs 35.7 ± 1.3%,P <0.001)。使用共聚焦荧光显微镜评估成纤维细胞中荧光标记的MMC @ MSNs-LDL的结合。成纤维细胞中靶向纳米颗粒的摄取是时间依赖性的,并且在6 h时饱和。VEGF激活的翼状胬肉成纤维细胞显示有或没有VEGF激活的正常成纤维细胞更多的MMC @ MSNs-LDL摄取 (均P <0.001)。我们的数据强烈表明,MMC @ MSNs-LDL在活化的翼状胬肉成纤维细胞中具有有效的抗增殖作用,与传统MMC相比,对正常成纤维细胞的毒性降低。LDL介导的药物递送在治疗翼状胬肉复发方面可能具有巨大潜力。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录